MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3109/00365513.2015.1099722

Медицинская библиотека · Scandinavian journal of clinical and laboratory investigation · 2015

Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.

Kazankov Konstantin, Rode Anthony, Simonsen Kira, Villadsen Gerda Elisabeth, Nicoll Amanda, Møller Holger Jon, Lim Lucy, Angus Peter, Kronborg Ian, Arachchi Niranjan, Gorelik Alexandra, Liew Danny, Vilstrup Hendrik, Frystyk Jan, Grønbæk Henning

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Tumor associated macrophages are present in hepatocellular carcinoma (HCC) and associated with a poor prognosis. The aim of the present study was to investigate the levels and dynamics of soluble (s)CD163, a specific macrophage activation marker, in patients with HCC.

METHODS

In a cohort from Australia, we studied 109 HCC patients, 116 patients with chronic liver disease (CLD), and 52 healthy controls. We examined associations between baseline sCD163 and parameters of HCC severity as well as overall and progression-free survival. In a cohort of 42 Danish HCC patients, we measured sCD163 at baseline and 1, 4 and 12 weeks after ablative treatment.

RESULTS

In the Australian cohort, median sCD163 was similarly increased in HCC (5.6[interquartile range 3.5-8.0] mg/L) and CLD (6.1[3.6-9.6] mg/L) patients as compared to controls (2.0[1.5-2.7] mg/L, p < 0.001). sCD163 correlated with Child-Pugh and MELD scores in both HCC and CLD patients. Patients with high sCD163 levels had shorter progression-free survival (p < 0.001), but not overall survival (p = 0.15). In the Danish cohort, patients with HCC progression at 12 weeks had an increase in sCD163. There was no association between sCD163 and HCC size, number, vascular invasion or metastasis in any of the cohorts.

CONCLUSIONS

We confirmed increased sCD163 levels in CLD and HCC patients associated with Child-Pugh and MELD scores and portal hypertension, but not with HCC size and number, or metastasis. As a novel finding, baseline sCD163 appeared to predict a rapid HCC progression, as sCD163 increased during follow-up in HCC patients who showed progression.

Для цитирования: Kazankov Konstantin, Rode Anthony, Simonsen Kira, Villadsen Gerda Elisabeth, Nicoll Amanda, Møller Holger Jon, Lim Lucy, Angus Peter, Kronborg Ian, Arachchi Niranjan, Gorelik Alexandra, Liew Danny, Vilstrup Hendrik, Frystyk Jan, Grønbæk Henning. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.. Scandinavian journal of clinical and laboratory investigation. 2015. DOI: 10.3109/00365513.2015.1099722.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.